Skip to main content
Premium Trial:

Request an Annual Quote

berBruker: Bruker Daltonics to Merge with Bruker AXS

NEW YORK, April 7 - Bruker Daltonics and Bruker AXS today announced plans to merge into a single entity that will focus on the life science and materials research market, "with an emphasis on advancing proteomics."


The combined company, to be named Bruker BioSciences (with the new Nasdaq ticker symbol BRKR), will offer a broad range of mass spectrometry and x-ray analysis technology platforms, including Bruker Daltonics' Proteineer mass spec-based protein analysis systems and Bruker AXS' X8 series of x-ray crystallography systems for structural proteomics.


The combined companies expect to generate an estimated $250-260 million in revenues over the course of 2003. The merger is expected to close over the summer.


Bruker AXS will merge into Bruker Daltonics, and each outstanding share of common stock of Bruker AXS will be converted into the right to receive 0.63 shares of common stock of Bruker Daltonics. Based on Bruker Daltonics' closing stock price of $2.95 on April 4, the value of the deal is approximately $103.6 million.


Bruker Daltonics and Bruker AXS will operate as independent subsidiaries of Bruker BioSciences, and will retain their present management teams. Frank Laukien, formerly president and CEO of Bruker Daltonics, will serve as president and CEO of the new company. Martin Haase will move from the position of president and CEO of Bruker AXS to serve as senior vice president of Bruker BioSciences, and Laura Francis, formerly CFO of Bruker AXS, will hold the same title in the parent company.


The ten-member board of directors of Bruker BioSciences will consist of board members from both Bruker Daltonics and Bruker AXS.


Further details on the proposed merger are available here.



The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.